Switching From Agonist to Antagonist Peptide Enabled Successful Targeted Radiation Therapy for a Previously Untreatable Neuroendocrine Tumor | Research

The takeaway

A patient with metastatic neuroendocrine tumor that couldn't be treated with standard agonist-based PRRT due to poor tracer uptake was successfully treated after switching to an antagonist-based somatostatin peptide (LM3) for both imaging and therapy.

Antagonist > Agonist
The antagonist peptide LM3 showed markedly superior tumor uptake compared to standard agonist DOTATOC in the same patient

What the researchers found

Standard agonist-based imaging (68Ga-DOTATOC PET/CT) showed insufficient tumor uptake, precluding conventional PRRT. Switching to the antagonist-based tracer (68Ga-NODAGA-LM3 PET/CT) revealed markedly superior and treatment-sufficient uptake in the same patient.

This directly translated to successful therapy: 4 cycles of 177Lu-DOTA-LM3 PRRT produced a positive treatment response. The case demonstrates both diagnostic superiority of antagonist over agonist somatostatin receptor imaging and the feasibility of antagonist-mediated PRRT in patients who fail agonist-based approaches.

Why it matters

Approximately 20-30% of neuroendocrine tumor patients show insufficient uptake on standard agonist-based imaging, excluding them from PRRT — one of the most effective targeted therapies for these cancers. This case demonstrates that antagonist-based peptides can detect and treat tumors that agonist peptides miss, potentially expanding PRRT eligibility to a significant population of currently untreatable patients.

How the study worked

This is a single-patient proof-of-concept case report with intraindividual comparison. The same patient underwent sequential PET/CT imaging with both the agonist tracer (68Ga-DOTATOC) and the antagonist tracer (68Ga-NODAGA-LM3), enabling direct comparison of tumor uptake. Following successful antagonist imaging, the patient received 4 cycles of antagonist-based PRRT (177Lu-DOTA-LM3) and treatment response was assessed.

What this study cannot tell us

This is a single case report — the lowest level of clinical evidence. The positive response is documented but specific imaging and response metrics are not detailed in the abstract. Long-term outcomes and durability of response are unknown. LM3-based PRRT is not yet widely available or approved, and larger studies are needed to establish safety and efficacy profiles compared to standard DOTATATE-based PRRT.

How to read the evidence

This is a single-patient case report providing intraindividual proof of concept. While the direct comparison in the same patient is compelling, case reports represent the lowest tier of clinical evidence and cannot establish generalizability.

When this study was published

Published in 2026, this reflects the cutting edge of somatostatin receptor antagonist-based theranostics, a field still transitioning from research to clinical practice.

The bigger picture

Somatostatin receptor antagonist-based theranostics is an emerging frontier in nuclear medicine. While agonist-based PRRT (using DOTATATE/DOTATOC) is the current standard, accumulating evidence suggests antagonist peptides bind more receptor sites and achieve higher tumor uptake. This case adds to the growing body of evidence supporting a paradigm shift from agonist to antagonist peptides in neuroendocrine tumor theranostics, with potential to expand treatment eligibility and improve outcomes.

Questions still open

What percentage of patients currently excluded from PRRT due to low agonist uptake could be rescued by antagonist-based approaches?
How does the safety profile of LM3-based PRRT compare to standard DOTATATE-based PRRT?
Should antagonist-based imaging become the first-line approach for evaluating PRRT eligibility in all NET patients?

Common questions

What's the difference between agonist and antagonist peptides for tumor targeting?

Agonist peptides activate the somatostatin receptor (like a key turning a lock), causing the receptor to be pulled inside the cell. Antagonist peptides bind to the receptor but don't activate it — they sit on the cell surface and actually bind to more receptor sites than agonists do. This means antagonist-based tracers and therapies can achieve higher tumor uptake, making tumors more visible on scans and delivering more radiation during treatment.

Why couldn't this patient receive standard PRRT?

Standard PRRT uses agonist-based peptides to deliver radiation to tumors. Before treatment, a PET scan checks if the tumor absorbs enough of the peptide tracer. This patient's tumor showed too little uptake on the standard agonist scan, meaning PRRT wouldn't effectively target the cancer. When the doctors used an antagonist peptide instead, the uptake was dramatically better — enough to proceed with treatment, which proved successful.

Read the original research

Superior NET Targeting by Switch From Agonist to Antagonist-mediated Somatostatin Receptor Theranostics Allowing Successful (LM3-based) PRRT of Otherwise Precluded mNET: Intraindividual Proof-of-concept.

Clinical nuclear medicine, 51(1), e25-e26

View on PubMed ↗Publisher’s paper ↗

Citation

Speicher, Tilman; Burgard, Caroline; Rosar, Florian; Bastian, Moritz; Bartholomä, Mark; Maus, Stephan; Ezziddin, Samer. (2026). Superior NET Targeting by Switch From Agonist to Antagonist-mediated Somatostatin Receptor Theranostics Allowing Successful (LM3-based) PRRT of Otherwise Precluded mNET: Intraindividual Proof-of-concept.. Clinical nuclear medicine, 51(1), e25-e26. https://doi.org/10.1097/RLU.0000000000005936